Interval Between SARS-CoV-2 Infection and COVID-19 Vaccination

Objectives

Guide the timing of COVID-19 vaccination following SARS-CoV-2 infection, including for eligible people who have previously been infected.[1]The guidance covers previous symptomatic and asymptomatic infection, as well as infection associated with prolonged post-COVID-19 symptoms.[1]

• Support vaccination of eligible individuals with prior SARS-CoV-2 infection.[1]
• Clarify the interval required between recognised infection and COVID-19 vaccination.[1]
• Address vaccination timing where infection occurs before a first dose or between first and second doses.[1]

Implementation

Implement vaccination without routine pre-vaccination testing for SARS-CoV-2 infection, as available vaccine studies indicate that COVID-19 vaccination can be administered safely to people with previous infection.[1]Apply a minimum 30-day interval between known SARS-CoV-2 infection and vaccination.[1]

• Vaccinate eligible people after symptomatic, asymptomatic, or prolonged post-COVID-19 infection.[1]
• Wait at least 30 days after known infection before administering a COVID-19 vaccine dose.[1]
• Apply the 30-day interval when infection precedes the first dose and when it occurs after the first dose but before the second dose.[1]
• Direct implementation towards provincial health departments, pharmaceutical services, district and primary healthcare managers, COVID-19 vaccine programme managers, vaccination-site managers, and vaccinators.[1]
• Note that monitoring indicators, reporting requirements, surveillance arrangements, evaluation methods, budgets, financing mechanisms, and resource requirements are not specified.[1]

Monitoring & Evaluation

Monitoring and accountability arrangements are limited to identifying the health-system audiences responsible for applying the guidance. These include provincial health departments, pharmaceutical services, district and primary healthcare managers, COVID-19 vaccine programme managers, vaccination-site managers, and vaccinators.[1]

• Apply the guidance through the named provincial, district, primary-care, programme, site-management, and vaccinator roles.[1]
• Note that the guidance does not specify monitoring indicators, reporting requirements, surveillance systems, evaluation methods, performance targets, data flows, or formal accountability mechanisms.[1]

Costing & Financing

No costing or financing framework is provided. The guidance does not specify programme budgets, vaccine-delivery costs, funding sources, resource-mobilisation measures, funding gaps, allocations, or economic assumptions.[1]

• Use no stated monetary estimate for implementing the minimum 30-day interval between known SARS-CoV-2 infection and COVID-19 vaccination, as none is provided.[1]
• Recognise that the guidance provides no stated budget implications for vaccinating eligible people with previous symptomatic, asymptomatic, or prolonged post-COVID-19 infection.[1]